This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
  • Home
  • /
  • Drugs
  • /
  • P
  • /
  • Pemetrexed
  • /
  • Pemetrexed PEMETREXED DISODIUM 1000 mg/40mL Zydus Lifesciences Limited
FDA Drug information

Pemetrexed

Read time: 1 mins
Marketing start date: 18 Nov 2024
...
 

Summary of product characteristics


Effective Time

20220526

Version

1

Spl Product Data Elements

pemetrexed pemetrexed disodium PEMETREXED DISODIUM PEMETREXED MANNITOL HYDROCHLORIC ACID SODIUM HYDROXIDE pemetrexed pemetrexed disodium PEMETREXED DISODIUM PEMETREXED MANNITOL HYDROCHLORIC ACID SODIUM HYDROXIDE pemetrexed pemetrexed disodium PEMETREXED DISODIUM PEMETREXED MANNITOL HYDROCHLORIC ACID SODIUM HYDROXIDE

Application Number

ANDA214073

Brand Name

Pemetrexed

Generic Name

pemetrexed disodium

Product Ndc

70771-1693

Product Type

HUMAN PRESCRIPTION DRUG

Route

INTRAVENOUS

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1691-1 Pemetrexed for Injection, USP 100 mg/vial For intravenous use only. Single-Dose Vial Rx only NDC 70771-1691-1 Pemetrexed for Injection, USP 100 mg/vial For intravenous use only. One Single-Dose Vial Carton Rx only NDC 70771-1692-1 Pemetrexed for Injection, USP 500 mg/vial For intravenous use only. Single-Dose Vial Rx only NDC 70771-1692-1 Pemetrexed for Injection, USP 500 mg/vial For intravenous use only. One Single-Dose Vial Carton Rx only NDC 70771-1693-1 Pemetrexed for Injection, USP 1000 mg/vial For intravenous use only. Single-Dose Vial Rx only NDC 70771-1693-1 Pemetrexed for Injection, USP 1000 mg/vial For intravenous use only. One Single-Dose Vial Carton Rx only 100 mg vial label 100 mg carton label 500 mg vial label 500 mg carton label 1,000 mg vial label 1,000 mg carton label

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.